Andrew Ryscavage

Andrew Ryscavage is a Sr. Principal at Scimitar. A [former] scientist, bio-strategist, and ad[venture]ist, he seeks to empower the bioeconomy through biotechnology and life science consulting and writing/teaching. He is often sought after to understand strategic blindspots or opportunities and for program management support.

Insights by Andrew Ryscavage

AI and Drug Discovery: The Virtual Lab’s Role in Revolutionizing Biopharma R&D

| Intended Reader Biopharma leaders | Key Takeaways AI-driven Virtual Labs are set to revolutionize biopharma R&D. …

Blog 3 min

Beyond the Shot: Biopharma's Quest for Lasting Drug Delivery

| Intended Reader Biopharma leaders | Key Takeaways GLP-1 drugs inspire broader therapeutic advancements. Long-lasting …

Blog 2 min

Concluding Thoughts on the Evolving World of Global Regulatory Affairs

| Intended Reader Biopharma leaders | Key Takeaways Striking a Balance Between Speed and Safety Global Collaboration …

Blog 2 min

The Evolving World of Global Regulatory Affairs: Shaping Regulatory Gold Standards and Processes

| Intended Reader Biopharma leaders | Key Takeaways Striking a Balance Between Speed and Safety Global Collaboration …

Blog 3 min

The Evolving World of Global Regulatory Affairs: The Impact of New Modalities

| Intended Reader Biopharma leaders | Key Takeaways Emerging Modalities: Cell and Gene Therapies Engineered Live …

Blog 3 min

The Evolving World of Global Regulatory Affairs: The Interplay between Harmonization, RWE/RWD, and AI

| Intended Reader Biopharma leaders | Key Takeaways Harmonization's impact on RWE and RWD integration Leveraging AI to …

Blog 2 min

The Evolving World of Global Regulatory Affairs: Embracing Artificial Intelligence (AI)

| Intended Reader Biopharma leaders | Key Takeaways Transforming Regulatory Processes with AI AI in Drug Discovery and …

Blog 3 min

The Evolving World of Global Regulatory Affairs: Navigating Change and Embracing Innovation

| Intended Reader Biopharma leaders | Key Takeaways Project Orbis is a case study for cross-market regulatory …

Blog 4 min